Clinicopathologic features in a cohort of GEA patients treated with second‐line FOLFIRI‐ram
| Clinicopathologic feature . | n = 29, n (%) . |
|---|---|
| Age at 2L initiation, median (range), yr | 61.5 (36–80) |
| Sex | |
| Male | 21 (72.4) |
| Female | 8 (27.6) |
| ECOG at 2L initiation | |
| 0 | 12 (45.2) |
| 1 | 14 (48.0) |
| 2 | 2 (6.9) |
| 3 | 1 (3.4) |
| Ethnicity | |
| Hispanic/Latino | 7 (24.1) |
| White | 16 (55.0) |
| Black | 3 (10.3) |
| Asian | 2 (6.9) |
| Other | 1 (3.4) |
| Tumor location | |
| Esophagus | 4 (13.8) |
| GEJ | 8 (27.6) |
| Gastric | 17 (58.6) |
| Stage at diagnosis | |
| II | 1 (3.4) |
| III | 6 (20.7) |
| IV | 22 (75.9) |
| Lauren histology | |
| Diffuse | 14 (48.3) |
| Intestinal | 13 (44.8) |
| NOS | 2 (6.9) |
| Histologic grade | |
| 1 (well differentiated) | 1 (3.4) |
| 2 (moderately differentiated) | 6 (20.7) |
| 3 (poorly differentiated) | 22 (75.9) |
| Signet ring cell features | |
| Yes | 14 (48.3) |
| No | 15 (51.7) |
| Ascites | |
| Yes | 13 (44.8) |
| No | 16 (55.2) |
| Metastatic disease sites | |
| Visceral | 15 (51.7) |
| Lymph node | 20 (70.0) |
| Radiographic peritoneal | 13 (44.8) |
| HER2 status at diagnosis | |
| IHC 0 | 17 (54.8) |
| IHC 1+ | 4 (12.9) |
| IHC 2+ | 4 (12.9) |
| IHC 2+, FISH/NGS amp | 1 |
| IHC 2+, FISH/NGS non‐amp | 3 |
| IHC 3+ | 1 (3.2) |
| Unknown | 2 (6.5) |
| Clinicopathologic feature . | n = 29, n (%) . |
|---|---|
| Age at 2L initiation, median (range), yr | 61.5 (36–80) |
| Sex | |
| Male | 21 (72.4) |
| Female | 8 (27.6) |
| ECOG at 2L initiation | |
| 0 | 12 (45.2) |
| 1 | 14 (48.0) |
| 2 | 2 (6.9) |
| 3 | 1 (3.4) |
| Ethnicity | |
| Hispanic/Latino | 7 (24.1) |
| White | 16 (55.0) |
| Black | 3 (10.3) |
| Asian | 2 (6.9) |
| Other | 1 (3.4) |
| Tumor location | |
| Esophagus | 4 (13.8) |
| GEJ | 8 (27.6) |
| Gastric | 17 (58.6) |
| Stage at diagnosis | |
| II | 1 (3.4) |
| III | 6 (20.7) |
| IV | 22 (75.9) |
| Lauren histology | |
| Diffuse | 14 (48.3) |
| Intestinal | 13 (44.8) |
| NOS | 2 (6.9) |
| Histologic grade | |
| 1 (well differentiated) | 1 (3.4) |
| 2 (moderately differentiated) | 6 (20.7) |
| 3 (poorly differentiated) | 22 (75.9) |
| Signet ring cell features | |
| Yes | 14 (48.3) |
| No | 15 (51.7) |
| Ascites | |
| Yes | 13 (44.8) |
| No | 16 (55.2) |
| Metastatic disease sites | |
| Visceral | 15 (51.7) |
| Lymph node | 20 (70.0) |
| Radiographic peritoneal | 13 (44.8) |
| HER2 status at diagnosis | |
| IHC 0 | 17 (54.8) |
| IHC 1+ | 4 (12.9) |
| IHC 2+ | 4 (12.9) |
| IHC 2+, FISH/NGS amp | 1 |
| IHC 2+, FISH/NGS non‐amp | 3 |
| IHC 3+ | 1 (3.2) |
| Unknown | 2 (6.5) |
Abbreviations: 2L, second‐line; amp, amplification; ECOG, Eastern Cooperative Oncology Group; FISH, fluorescence in situ hybridization; GEA, gastroesophageal adenocarcinoma; GEJ, gastroesophageal junction; IHC, immunohistochemistry; NGS, next‐generation sequencing; NOS, not otherwise specified; ram, ramucirumab.
Clinicopathologic features in a cohort of GEA patients treated with second‐line FOLFIRI‐ram
| Clinicopathologic feature . | n = 29, n (%) . |
|---|---|
| Age at 2L initiation, median (range), yr | 61.5 (36–80) |
| Sex | |
| Male | 21 (72.4) |
| Female | 8 (27.6) |
| ECOG at 2L initiation | |
| 0 | 12 (45.2) |
| 1 | 14 (48.0) |
| 2 | 2 (6.9) |
| 3 | 1 (3.4) |
| Ethnicity | |
| Hispanic/Latino | 7 (24.1) |
| White | 16 (55.0) |
| Black | 3 (10.3) |
| Asian | 2 (6.9) |
| Other | 1 (3.4) |
| Tumor location | |
| Esophagus | 4 (13.8) |
| GEJ | 8 (27.6) |
| Gastric | 17 (58.6) |
| Stage at diagnosis | |
| II | 1 (3.4) |
| III | 6 (20.7) |
| IV | 22 (75.9) |
| Lauren histology | |
| Diffuse | 14 (48.3) |
| Intestinal | 13 (44.8) |
| NOS | 2 (6.9) |
| Histologic grade | |
| 1 (well differentiated) | 1 (3.4) |
| 2 (moderately differentiated) | 6 (20.7) |
| 3 (poorly differentiated) | 22 (75.9) |
| Signet ring cell features | |
| Yes | 14 (48.3) |
| No | 15 (51.7) |
| Ascites | |
| Yes | 13 (44.8) |
| No | 16 (55.2) |
| Metastatic disease sites | |
| Visceral | 15 (51.7) |
| Lymph node | 20 (70.0) |
| Radiographic peritoneal | 13 (44.8) |
| HER2 status at diagnosis | |
| IHC 0 | 17 (54.8) |
| IHC 1+ | 4 (12.9) |
| IHC 2+ | 4 (12.9) |
| IHC 2+, FISH/NGS amp | 1 |
| IHC 2+, FISH/NGS non‐amp | 3 |
| IHC 3+ | 1 (3.2) |
| Unknown | 2 (6.5) |
| Clinicopathologic feature . | n = 29, n (%) . |
|---|---|
| Age at 2L initiation, median (range), yr | 61.5 (36–80) |
| Sex | |
| Male | 21 (72.4) |
| Female | 8 (27.6) |
| ECOG at 2L initiation | |
| 0 | 12 (45.2) |
| 1 | 14 (48.0) |
| 2 | 2 (6.9) |
| 3 | 1 (3.4) |
| Ethnicity | |
| Hispanic/Latino | 7 (24.1) |
| White | 16 (55.0) |
| Black | 3 (10.3) |
| Asian | 2 (6.9) |
| Other | 1 (3.4) |
| Tumor location | |
| Esophagus | 4 (13.8) |
| GEJ | 8 (27.6) |
| Gastric | 17 (58.6) |
| Stage at diagnosis | |
| II | 1 (3.4) |
| III | 6 (20.7) |
| IV | 22 (75.9) |
| Lauren histology | |
| Diffuse | 14 (48.3) |
| Intestinal | 13 (44.8) |
| NOS | 2 (6.9) |
| Histologic grade | |
| 1 (well differentiated) | 1 (3.4) |
| 2 (moderately differentiated) | 6 (20.7) |
| 3 (poorly differentiated) | 22 (75.9) |
| Signet ring cell features | |
| Yes | 14 (48.3) |
| No | 15 (51.7) |
| Ascites | |
| Yes | 13 (44.8) |
| No | 16 (55.2) |
| Metastatic disease sites | |
| Visceral | 15 (51.7) |
| Lymph node | 20 (70.0) |
| Radiographic peritoneal | 13 (44.8) |
| HER2 status at diagnosis | |
| IHC 0 | 17 (54.8) |
| IHC 1+ | 4 (12.9) |
| IHC 2+ | 4 (12.9) |
| IHC 2+, FISH/NGS amp | 1 |
| IHC 2+, FISH/NGS non‐amp | 3 |
| IHC 3+ | 1 (3.2) |
| Unknown | 2 (6.5) |
Abbreviations: 2L, second‐line; amp, amplification; ECOG, Eastern Cooperative Oncology Group; FISH, fluorescence in situ hybridization; GEA, gastroesophageal adenocarcinoma; GEJ, gastroesophageal junction; IHC, immunohistochemistry; NGS, next‐generation sequencing; NOS, not otherwise specified; ram, ramucirumab.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
